On April 22, 2026, the Italian Medicines Agency (AIFA) Board of Directors approved reimbursement by the Italian National Health Service (SSN) for four new medicines, including Agamree (vamorolone) for the treatment of Duchenne muscular dystrophy (DMD) in patients aged 4 years and older.
The decision, announced during AIFA’s April 22 meeting, marks a significant step in expanding access to innovative therapies for rare diseases in Italy. Alongside vamorolone, the reimbursement package includes Nemluvio (nemolizumab) for atopic dermatitis and prurigo nodularis, Trecondi (treosulfan) for hematopoietic stem cell transplantation conditioning, and Welireg (belzutifan) for certain tumors associated with von Hippel-Lindau disease.
Vamorolone, marketed as Agamree, is a dissociative steroid designed to deliver anti-inflammatory benefits similar to glucocorticoids while reducing the risk of adverse side effects commonly associated with long-term corticosteroid use. Its approval for DMD follows a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) earlier in 2026 and aligns with the U.S. Food and Drug Administration’s (FDA) 2023 authorization of the drug for individuals aged 2 years and older.
Clinical evidence supporting the AIFA decision comes from the VISION-DMD study, which evaluated ambulatory boys aged 4 to 7 years across 33 international trial sites. The study demonstrated that vamorolone improved time to stand test velocity compared to placebo and showed a favorable safety and tolerability profile relative to prednisone, a standard corticosteroid treatment.
Duchenne muscular dystrophy is a rare genetic disorder characterized by progressive muscle degeneration and weakness, primarily affecting boys. It leads to loss of ambulation, respiratory and cardiac complications, and significantly reduced life expectancy. The availability of reimbursed treatments like vamorolone represents a meaningful advancement in managing the disease’s progression and improving quality of life for patients and families.
Details on the Four Newly Reimbursed Medicines
AIFA’s April 22 decision encompassed four distinct therapeutic areas, reflecting a broad commitment to innovation in Italian healthcare policy.
Agamree (vamorolone) is indicated for Duchenne muscular dystrophy in patients aged 4 years and older. As a selective glucocorticoid receptor modulator, it aims to mitigate inflammation without the full spectrum of steroid-related side effects such as weight gain, bone density loss, and growth suppression.
Nemluvio (nemolizumab) is a monoclonal antibody targeting the interleukin-31 receptor alpha, approved for moderate-to-severe atopic dermatitis and prurigo nodularis in adults who are candidates for systemic therapy. It works by inhibiting a key cytokine involved in chronic itch and skin inflammation.
Trecondi (treosulfan), when used in combination with fludarabine, serves as a conditioning regimen prior to allogeneic hematopoietic stem cell transplantation. It is particularly valued for its reduced toxicity profile compared to traditional busulfan-based regimens, making it suitable for older patients or those with comorbidities.
Welireg (belzutifan) is a hypoxia-inducible factor-2 alpha (HIF-2α) inhibitor indicated for adults with von Hippel-Lindau (VHL) disease who require therapy for associated renal cell carcinoma, central nervous system hemangioblastomas, or pancreatic neuroendocrine tumors, and who do not require immediate surgery.
Context and Significance of AIFA’s Reimbursement Decision
The reimbursement approvals follow a structured evaluation process in which AIFA assesses clinical efficacy, safety, economic impact, and unmet medical need. By including these medicines in the SSN formulary, the agency ensures that eligible patients across Italy can access them without prohibitive out-of-pocket costs.
For rare diseases like Duchenne muscular dystrophy and von Hippel-Lindau syndrome, where patient populations are small and treatment development is costly, national reimbursement decisions play a critical role in determining real-world accessibility. AIFA’s move aligns with broader European efforts to harmonize access to orphan medicines while maintaining fiscal sustainability in public health systems.
The inclusion of vamorolone also reflects growing confidence in dissociative steroids as a safer alternative to conventional glucocorticoids in chronic inflammatory conditions. Ongoing research continues to explore its potential applications beyond DMD, including in other neuromuscular and autoimmune disorders.
Stakeholder Impact and Patient Access
Patients diagnosed with Duchenne muscular dystrophy typically begin corticosteroid treatment around the time of diagnosis, often between ages 2 and 5, to delay loss of muscle function. With vamorolone now reimbursed from age 4, Italian families have access to an alternative that may offer comparable efficacy with a improved side effect profile, particularly important during critical growth years.
Healthcare providers prescribing these medicines must adhere to AIFA’s indications and monitoring guidelines. For vamorolone, this includes regular assessments of growth, bone health, and adrenal function, consistent with recommendations for long-term steroid therapy management.
Patient advocacy groups have welcomed the decision, noting that timely access to approved therapies can significantly influence disease trajectory. They continue to work with AIFA and regional health authorities to ensure equitable distribution and ongoing monitoring of real-world outcomes.
Next Steps and Official Updates
The next official update on pharmaceutical reimbursements in Italy is expected from AIFA’s subsequent Board of Directors meeting, scheduled for May 27, 2026, based on the agency’s published calendar. Stakeholders can access meeting agendas, minutes, and formal resolutions through AIFA’s official website (Agenzia Italiana del Farmaco).
For ongoing updates on orphan drug approvals and rare disease treatments in Europe, the European Medicines Agency provides centralized information via its human medicines portal (European Medicines Agency).
Readers are encouraged to consult their healthcare providers for personalized medical advice and to refer to official sources for the most accurate and current information on treatment availability and reimbursement policies.